Opinion|Videos|January 13, 2025
Proactive CRS Management: The Role of Tocilizumab and Beyond
Author(s)Amrita Krishnan, MD
Amrita Krishnan, MD, discusses how data from ASH 2024 highlight the critical role of intravenous immunoglobulin (IVIG) treatment in preventing infections in patients receiving teclistamab, shares her approach to incorporating IVIG into clinical practice, and outlines additional strategies for reducing infection risk and managing cytokine release syndrome (CRS) in patients on bispecific antibody therapies for multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Data from ASH 2024 suggest intravenous immunoglobulin (IVIG) can play a critical role in preventing infections in patients receiving teclistamab. How do you incorporate IVIG into your clinical practice, and what considerations guide its use?
- Beyond IVIG, what additional strategies or prophylactic measures have you incorporated into your practice to reduce infection risk in patients on bispecific antibody therapies in multiple myeloma?
- Cytokine release syndrome (CRS) remains a common concern with bispecific antibodies. What strategies do you find most effective for managing CRS?
Advertisement
Related to this article
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
A review of 47 endometriosis guidelines found most came from high-income settings and diverged on biomarkers, repeat surgery, and fertility referral.
The meeting covered several topics in eye care, including how artificial intelligence (AI) can play a part in eye care.
A meta-analysis of 27 trials found a 15% cardiovascular risk reduction per 10-mm Hg lower systolic BP, with no added risk of kidney failure.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
2
New CHEST Guidelines Offer a Road Map for Bronchiectasis
3
FDA Grants Accelerated Approval to Dostarlimab for dMMR Rectal Cancer
4
CHEST Highlights Practice-Changing COPD Therapy and Strategies
5